256 related articles for article (PubMed ID: 9740155)
1. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin.
Fogel MA; Nussbaum PB; Feintzeig ID; Hunt WA; Gavin JP; Kim RC
Am J Kidney Dis; 1998 Sep; 32(3):401-9. PubMed ID: 9740155
[TBL] [Abstract][Full Text] [Related]
2. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations.
Marx MA; Frye RF; Matzke GR; Golper TA
Am J Kidney Dis; 1998 Sep; 32(3):410-4. PubMed ID: 9740156
[TBL] [Abstract][Full Text] [Related]
3. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
Stryjewski ME; Szczech LA; Benjamin DK; Inrig JK; Kanafani ZA; Engemann JJ; Chu VH; Joyce MJ; Reller LB; Corey GR; Fowler VG
Clin Infect Dis; 2007 Jan; 44(2):190-6. PubMed ID: 17173215
[TBL] [Abstract][Full Text] [Related]
4. Appropriateness of empiric gentamicin and vancomycin therapy for bacteremias in chronic dialysis outpatient units in the era of antibiotic resistance.
Krol V; Cunha BA; Schoch PE; Klein NC
J Chemother; 2006 Oct; 18(5):490-3. PubMed ID: 17127225
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin-resistant enterococcus in end-stage renal disease.
Brady JP; Snyder JW; Hasbargen JA
Am J Kidney Dis; 1998 Sep; 32(3):415-8. PubMed ID: 9740157
[TBL] [Abstract][Full Text] [Related]
6. Use of cefazolin for peritonitis treatment in peritoneal dialysis patients.
Agraharkar M; Klevjer-Anderson P; Rubinstien E; Galen M
Am J Nephrol; 1999; 19(5):555-8. PubMed ID: 10575183
[TBL] [Abstract][Full Text] [Related]
7. Management of gram-positive coccal bacteremia and hemodialysis.
Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
[TBL] [Abstract][Full Text] [Related]
9. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients.
Pfundstein J; Roghmann MC; Schwalbe RS; Qaiyumi SQ; McCarter RJ; Keay S; Schweitzer E; Bartlett ST; Morris JG; Oldach DW
Clin Transplant; 1999 Jun; 13(3):245-52. PubMed ID: 10383105
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic selection for the treatment of infectious complications of implant-based breast reconstruction.
Weichman KE; Levine SM; Wilson SC; Choi M; Karp NS
Ann Plast Surg; 2013 Aug; 71(2):140-3. PubMed ID: 23486147
[TBL] [Abstract][Full Text] [Related]
12. Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection.
Onyeji CO; Nicolau DP; Nightingale CH; Bow L
J Antimicrob Chemother; 2000 Sep; 46(3):429-36. PubMed ID: 10980170
[TBL] [Abstract][Full Text] [Related]
13. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Huang V; Rybak MJ
Antimicrob Agents Chemother; 2005 Jan; 49(1):302-8. PubMed ID: 15616309
[TBL] [Abstract][Full Text] [Related]
15. Comparative prophylactic efficacy of cefazolin and vancomycin in a guinea pig model of Staphylococcus aureus wound infection.
Kernodle DS; Kaiser AB
J Infect Dis; 1993 Jul; 168(1):152-7. PubMed ID: 8515103
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial.
Maki DG; Bohn MJ; Stolz SM; Kroncke GM; Acher CW; Myerowitz PD
J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1423-34. PubMed ID: 1434726
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections.
Finkelstein R; Rabino G; Mashiah T; Bar-El Y; Adler Z; Kertzman V; Cohen O; Milo S
J Thorac Cardiovasc Surg; 2002 Feb; 123(2):326-32. PubMed ID: 11828293
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.
Chan KE; Warren HS; Thadhani RI; Steele DJ; Hymes JL; Maddux FW; Hakim RM
J Am Soc Nephrol; 2012 Sep; 23(9):1551-9. PubMed ID: 22904350
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
20. Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomised controlled study.
Kelsey SM; Shaw E; Newland AC
J Chemother; 1992 Apr; 4(2):107-13. PubMed ID: 1629747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
